Clinical Trial Update: Bioequivalence Study of Escitalopram Tablets 10 mg [Phase 1]

View source ↗

Summary

GlaxoSmithKline completed a Phase 1 bioequivalence study of escitalopram 10 mg tablets for anxiety disorders.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anxiety Disorders

Drugs mentioned

• Escitalopram (generic) (escitalopram)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Anxiety Disorders | Phase 1 | Status: COMPLETED